Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adamis Pharma (ADMP) and Johnson & Johnson (JNJ).
Adamis Pharma (ADMP)
Raymond James analyst Elliot Wilbur maintained a Hold rating on Adamis Pharma today. The company’s shares closed last Tuesday at $1.64.
According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.8% and a 46.6% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Adamis Pharma has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Johnson & Johnson (JNJ)
In a report released today, Jayson Bedford from Raymond James maintained a Buy rating on Johnson & Johnson. The company’s shares closed last Tuesday at $170.48.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 17.1% and a 73.2% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Integra Lifesciences.
Johnson & Johnson has an analyst consensus of Strong Buy, with a price target consensus of $177.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JNJ: